Exit

Dark Matter Bio Longevity Fund II

Extending Human Healthspan Through Breakthrough Biotechnology

$100M Target | Seed to Series A/B | Vintage 2025

General Partners

  • Skinner Layne
  • Mark Moline
  • Anthony Borquez
  • Thomas Vu

Contact: fund@darkmatter.bio

Executive Summary

Mission: Invest in biotech innovations targeting aging mechanisms to extend healthspan and combat age-related diseases.

  • Projected IRR: 25-30%
  • Expected MOIC: 10x over 10 years
  • Portfolio: 25-30 high-impact longevity startups

Why Now?

  • Global aging population: 2B people over 60 by 2050
  • Breakthroughs in CRISPR, senolytics, and AI-driven drug discovery
  • $5B+ VC investment in longevity startups in 2024

Join us to capture the $7T longevity economy.

The Problem: The Aging Crisis

Challenge: Age-related diseases cost $1T+ annually in global healthcare

  • Alzheimer's, cancer, cardiovascular disease, diabetes, renal failure
  • Average healthspan (65 years) lags lifespan (80+ years)
  • 20% of U.S. population over 65 by 2030

Opportunity: Biotech solutions can extend healthspan, reduce costs, and improve lives.

Market Opportunity

Total Addressable Market: $600B+ by 2030

  • Therapeutics: $200B (senolytics, gene therapies, novel molecules)
  • Diagnostics: $100B (aging biomarkers, predictive testing)
  • Platforms: $150B (AI drug discovery, practice management)

15% CAGR in longevity biotech through 2035

Investment Thesis

Core Belief: Targeting the hallmarks of aging unlocks multi-disease therapies.

Focus Areas:

  • Cellular rejuvenation (stem cell, exosome therapies)
  • Precision medicine (genomic diagnostics, gene therapies)
  • AI-driven drug discovery

Our Differentiation

  • Deep scientific expertise in longevity biology
  • Proprietary deal flow via Stanford, Cedars-Sinai partnerships
  • Relationships with longevity leaders: Ben Greenfield, Bryan Johnson, Peter Attia
  • Focus on IP-protected, scalable solutions

Exit Potential

  • IPOs in public markets
  • Acquisitions by big pharma
  • Example: Pfizer's 2024 acquisition of a senolytics startup

Fund Strategy

Fund Size: $100M | Term: 10 years

Fees: 2% management, 20-25% carried interest

Geography: 70% U.S./Europe, 30% global

Stages: Seed (50%), Series A/B (30%), Follow-ons (20%)

Investment Approach

  1. 25 primary investments
  2. $2.75M - $3.0M initial checks
  3. $5M - $10M reserved for top performers
  4. Follow-on allocation:
    • Top 3-5 companies: $5M-$10M+ total
    • Next 8-10: $3M-$5M total
    • Rest: pro-rata only

Track Record: MarsBio Fund I

Performance:

  • 5.2x MOIC
  • 419% net IRR
  • $60,000 distribution, 1 exit

Portfolio Highlights

Company Stage Valuation Initial Investment
AmberCycle Series B $270M $2.5M
MiniCircle Series B $200M $2.5M
Encellin Series B $100M $20M
Inaru Series B $100M $4M

Team: General Partners

Mark Moline - 15 years in VC, multiple exits, 6x unicorn investor

Anthony Borquez - Two-time exited founder, USC professor

Skinner Layne - Biotech VC experience

Thomas Vu - Investment expertise

Advisory Board

Dr. Keith Black - Chairman, Cedars-Sinai Neurological Sciences Dept.

Dr. Michael Snyder - Chairman, Stanford Genetics Department

Dr. Bruce Johnson - Mayo Clinic

Competitive Positioning

DMBL Fund II vs. Peers

  • Specialized focus on biotech vs. broader AgeTech
  • Proprietary deal flow from academic partnerships
  • First-mover in emerging longevity sub-sectors
  • Underfunded gaps: non-pharma interventions (nutraceuticals)

Financial Projections

Base Case:

  • Net IRR: 25-30%
  • MOIC: 10x over 10 years
  • Deployment: $80M over 3-4 years

Exit Scenarios: 50% IPOs, 40% acquisitions, 10% other

Sensitivity Analysis

Scenario MOIC
Conservative 3x
Base Case 10x
Optimistic 12x

Risks

  • Scientific: Clinical trial failures (30% fail Phase II)
  • Regulatory: Delays in FDA/EMA approvals
  • Market: Economic downturns impacting biotech funding

Risk Mitigations

  • Rigorous due diligence by scientific advisors
  • Diversified portfolio across sub-sectors
  • Staged investments to limit exposure

Sustainability & Impact

Mission: Make longevity therapies accessible and equitable

Impact Goals:

  • Add 10+ healthy years to global lifespans
  • Reduce $1T healthcare burden from age-related diseases

Supports UN SDG #3: Good Health and Well-Being

Call to Action

Join Us: Invest in DMBL Fund II to shape the future of longevity

Minimum Commitment: $5M

Deadlines:

  • Carry discount: December 31, 2025
  • Full carry: March 2026

Contact Us

Schedule a meeting:

Due diligence materials available for qualified investors.

Together, we can redefine aging.

Appendix: Market Data

Sources:

  • McKinsey: $600B longevity biotech market by 2030
  • WHO: 2B people over 60 by 2050
  • PitchBook: $5B VC investment in longevity (2024)

Additional Stats:

  • 15% CAGR in longevity biotech
  • 50% increase in FDA fast-tracked longevity drugs (2023-2025)

Legal Disclaimers

Past performance is not indicative of future results. Investments involve risks, including loss of capital.

Accredited Investors Only: DMBL Fund II is open to qualified investors per SEC regulations.

Confidentiality: This deck is for intended recipients only; do not distribute.